The anti-tumor effects of entinostat in ovarian cancer require adaptive immunity

BACKGROUND: Ovarian cancer is poorly immunogenic; however, increased major histocompatibility complex class II (MHCII) expression correlates with improved immune response and prolonged survival in ovarian cancer patients. We previously demonstrated that the histone deacetylase inhibitor entinostat i...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Cancer
Huvudupphovsmän: Smith, Haller J., McCaw, Tyler R., Londono, Angelina I., Katre, Ashwini A., Meza-Perez, Selene, Yang, Eddy S., Forero, Andres, Buchsbaum, Donald J., Randall, Troy D., Straughn, J. Michael, Norian, Lyse A., Arend, Rebecca C.
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2018
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6294677/
https://ncbi.nlm.nih.gov/pubmed/30423192
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.31761
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk